Pediatric growth hormone treatment in Italy: A systematic review of epidemiology, quality of life, treatment adherence, and economic impact.
Massimiliano OrsoBarbara PolistenaSimona GranatoGiuseppe NovelliRoberto Di VirgilioDaria La TorreDaniela d'AngelaFederico SpandonaroPublished in: PloS one (2022)
Growth failure conditions with approved GH treatment in Italy constitute a significant burden of disease in clinical, social, and economic terms. GH treatment is generally considered acceptable by patients and caregivers. The total cost of the GH treatment is considerable; there are margins for improving efficiency, by increasing adherence, reducing drug wastage and promoting prescriptive appropriateness.